Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTX-2002 in Advanced HCC and MYC-associated Solid Tumors
NCT05497453Phase 2Terminated
- Sponsor
- Omega Therapeutics
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of OTX-2002 in hepatocellular carcinoma (HCC) and solid tumor (4 arms), sponsored by Omega Therapeutics. Primary endpoints: Dose limiting toxicities at 28 days, Maximum Tolerated Dose at 28 days and 3 more. Started Aug 2022; status: terminated.
02
Drugs
OTX-2002
03
Conditions
hepatocellular carcinoma (HCC)solid tumor
Beyond the preview
Go deeper on NCT05497453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497453.